Miroestrol

Miroestrol

Identity: Botanical Source, Chemical Nature, and Common Forms

Botanical Source and Nomenclature

Miroestrol is a phytoestrogen — a plant-derived chemical that mimics the biological activity of the hormone estrogen. It is a rare phytoestrogenic compound found almost exclusively in the tuberous roots of Pueraria mirifica. The plant is also formally known as Pueraria candollei var. mirifica (Airy Shaw & Suvatabandhu) Niyomdham, and it belongs to the family Leguminosae (Fabaceae). In Thailand, the plant is known as Kwao Krua Kao, the word Kao meaning "white," which distinguishes Pueraria mirifica from other plants with tuberous roots also sharing the Kwao Krua designation, such as Butea superba, commonly called Kwao Krua Deng (Red) and the Black and Dull Grey Kwao Krua plants.

Evidence of the use of Pueraria mirifica can be identified as early as the 13th century. The species was definitively identified as Pueraria mirifica in 1952.

Chemical Identity and Structure

Three major types of phytoestrogens occur in P. mirifica: isoflavones, coumestans, and chromenes. Miroestrol is considered the primary active compound responsible for the plant's estrogen-like activity. Chemically, it belongs to a class of compounds known as chromene derivatives, and its molecular structure closely resembles 17β-estradiol, the main estrogen hormone in humans.

The aromatic ring with the phenolic hydroxyl group at position 3 is present in both miroestrol and estradiol-17β. The β-hydroxyl group at position 18 in miroestrol corresponds to the 17β-hydroxyl group of estradiol-17β and the β-hydroxyl group in the 17 position of estriol. The 17α-hydroxyl group of miroestrol corresponds to the 16α-hydroxyl group of estriol. Miroestrol is thus a unique phytoestrogen that is very similar to estriol while being non-hormonal and non-steroidal.

Critically, the actual existence of miroestrol as a naturally occurring compound independent of its precursor is the subject of scientific debate. Miroestrol was first reportedly isolated from the Thai herb Pueraria mirifica in 1960 and thought to be responsible for the supposed rejuvenating properties of the plant. However, more recent studies have suggested that the active ingredient may actually be the closely related chemical compound deoxymiroestrol, and the reported presence of miroestrol may only have been an artifact of the isolation procedure — because when deoxymiroestrol is exposed to oxygen in air, it is converted to miroestrol. This finding was the subject of a landmark paper published in the Journal of Natural Products (Chansakaow et al., 2000). Reinvestigation using bioassay-guided purification resulted in the isolation of a new potent phytoestrogen, deoxymiroestrol, and the facile aerial oxidation of deoxymiroestrol into miroestrol suggests the possibility that miroestrol may be an artifact. There is thus contradictory evidence for the presence of miroestrol in P. mirifica as a native compound.

Miroestrol and its precursor deoxymiroestrol are typically accumulated at very low levels; however, these compounds are the predominant chromenes in the tuberous cortex of P. mirifica, and both compounds exhibit the highest estrogenic activity. Since both chromenes have not been reported in other plant species, their biosynthesis is likely unique to P. mirifica.

Miroestrol is a unique chromene found in White Kwao Krua (WKK) tuberous roots that corresponds to the estrogenic activity of WKK. However, miroestrol naturally accumulates at low levels in WKK samples, which are difficult to detect. The plant is estimated to contain miroestrol in amounts of around 0.17%.

Accompanying Phytochemical Constituents

Pueraria mirifica contains various phytoestrogens, including deoxymiroestrol, daidzin, daidzein, genistin, genistein, coumestrol, kwakhurin, and mirificine, as well as β-sitosterol, stigmasterol, campesterol, and mirificoumestan. Isoflavones are an important type of phytoestrogen, biosynthesized via the phenylpropanoid pathway and occurring predominantly in leguminous plants. Seven isoflavones have been identified in P. mirifica tubers: puerarin, daidzin, genistin, daidzein, genistein, kwakhurin, and mirificin. Four coumestans also occur in the tuber of this plant: coumestrol, mirificoumestan, mirificoumestan hydrate, and mirificoumestan.

Common Forms and Preparations

PM is available in tablets, extracts, creams, sprays, and powdered forms, so that it can be added to other medicinal preparations or herbs; individual conditions require different applications and dosages. Commercial products are available in topical (creams, gels, and soaps) or oral (capsules or tablets) dosage forms. It can be readily obtained from internet resources in many countries, including the USA and Japan, and is primarily used for supporting memory, smoothing the skin, increasing hair growth, improving appetite, and providing relief for ailments like osteoporosis.

Traditional and Historical Use

Geographic and Cultural Context

Dried and powdered, the tuberous root of Pueraria mirifica has a history of domestic consumption in Thailand in traditional folk medicine as a rejuvenating herb to promote youthfulness in both women and men, and is used widely within the now government-regulated practice of traditional Thai medicine. Evidence of the use of Pueraria mirifica can be definitively identified as early as the 13th century. Pueraria candollei var. mirifica, growing in upland Thailand, has a long history as a postmenopausal rejuvenating therapy for indigenous people.

Key Historical Documentation

Local communities in Thailand have used Pueraria mirifica for well over one hundred years, specifically for its rejuvenating qualities. The belief in the rejuvenating properties of PM has been passed down from one generation to another, and more recently through a publication by Luang Anusan Suntara. In May 1931, Luang Anusan Suntara published a pamphlet on the subject of "Kwao Krua," describing different ways of preparing folk medicine using Pueraria mirifica and the claims of its rejuvenating power. It is stated in the pamphlet that Pueraria mirifica can serve as an anti-wrinkle agent for aged and wrinkled skin, darken white hair and increase hair growth, alleviate cataract problems, help with memory loss, increase energy and vigor, increase blood circulation, improve appetite, and alleviate sleep disorders.

Preparation Methods in Traditional Practice

Dried and powdered, the tuberous root of Pueraria mirifica has a history of domestic consumption in Thailand in traditional folk medicine as a rejuvenating herb to promote youthfulness in both women and men. Traditional Thai herbal medicine often described the plant as a rejuvenating tonic for women, used to promote vitality and maintain feminine health. Although these traditional uses were based on observation rather than modern biochemical research, later scientific investigations confirmed that the plant contains chemical compounds that act as estrogen-like compounds, which are not commonly found in other botanical species.

Key Constituents and Mechanisms of Action

Estrogen Receptor Binding

Evidence shows that miroestrol binds with higher affinity to estrogen receptor α (ERα) than other isoflavonoids isolated from this plant (Sugiyama et al., 2009). Variations in the estrogenic activity of P. mirifica were determined using a yeast estrogen screen consisting of human estrogen receptors hERα and hERβ. Relative estrogenic potency was expressed by determining the β-galactosidase activity (EC50) of the tuber extracts in relation to 17β-estradiol. Twenty-four and 22 of the plant tuber ethanolic extracts interacted with hERα and hERβ, respectively, with a higher relative estrogenic potency with hERβ than with hERα.

A comparative study of the estrogenic properties of phytoestrogens found that both deoxymiroestrol and miroestrol were comparable in activity in vitro to other known phytoestrogens such as coumestrol as 17β-estradiol agonists. Estrogenic activity of miroestrol was first investigated in rat and shown that it produced a mammogenic effect. Miroestrol exhibited estrogenic activity 0.25 times that of 17β-estradiol as measured by vaginal cornification assay.

Estrogens exert their actions by binding to specific receptors, the estrogen receptors (ERs), which in turn activate transcriptional processes and/or signaling events that result in the control of gene expression. These actions can be mediated by direct binding of estrogen receptor complexes to specific sequences in gene promoters (genomic effects), or by mechanisms that do not involve direct binding to DNA (non-genomic effects). Miroestrol appears to activate the same receptor-mediated pathways as endogenous estrogens, by virtue of its structural homology with estriol and estradiol.

Antioxidant Mechanisms

Miroestrol increased the levels of glutathione and the activity of antioxidant enzymes in the liver and uterus of β-naphthoflavone-treated mice, and exhibited a preventive effect against bone loss in ovariectomized mice (Udomsuk et al., 2012). Miroestrol, as an active phytoestrogen in P. mirifica, is reported to have the ability to improve the capacity of the antioxidant system to counterbalance oxidative stress in vivo.

Proposed Biosynthetic Origin

Miroestrol biosynthesis was reconsidered and the most plausible mechanism starting from the isoflavonoid daidzein was proposed. Although miroestrol has been identified for almost six decades, its biosynthetic pathway and the enzymes involved are still unknown.

Scientific Evidence by Area of Use

1. Menopausal Symptom Relief

The most extensively studied application of P. mirifica — and by extension, miroestrol as its primary chromene constituent — is the relief of menopausal symptoms. A systematic review identified eight studies (nine articles) using data from 309 menopausal patients. Five studies demonstrated that PM was associated with climacteric scores reduced by approximately 50% compared to baseline.

To evaluate the preliminary efficacy and safety of Pueraria mirifica for the alleviation of climacteric symptoms, perimenopausal women presenting with hot flushes and night sweats were invited to join a study at the Menopausal Clinic, Hat Yai Regional Hospital. The patients were voluntarily enrolled and randomly received either 50 mg or 100 mg capsules of raw Pueraria mirifica material once daily for six months, as an open-label study. Of the 10 enrolled patients, 8 cases were completely evaluated. The modified Greene climacteric scale (MGCS) was satisfactorily decreased in both groups, declining from an average of 44.1 at baseline to 26, 17, and 11.1 at 1-, 3-, and 6-month follow-up, respectively. Both dosages were similarly effective and safe in the treatment of menopausal symptoms. Limitation: This was a small open-label study with only 8 evaluable participants and no placebo control.

Continuous administration of PM at 20–100 mg/day for 6 months, or at 100–200 mg/day for 12 months, was found to help women with menopausal symptoms, while no significant changes were detected in hepatic, hematologic, and renal functions.

Small studies suggest that Pueraria mirifica may help ease some symptoms of menopause, including hot flashes, vaginal dryness, irritability, and irregular periods, but recent reviews of these studies have been inconclusive, so the jury is still out on whether these claims can be supported.

2. Vulvovaginal and Genitourinary Atrophy

One of the most consistent findings in clinical research is improvement in vulvovaginal symptoms. In a randomized, placebo-controlled trial of healthy postmenopausal women, daily Pueraria mirifica at doses around 20–50 mg improved vaginal dryness, discomfort during intercourse, and clinical measures of vaginal atrophy over several months. The treatment group showed changes in vaginal cell types and pH that resemble those seen with low-dose estrogen therapy, along with symptom relief.

A randomized, double-blinded, placebo-controlled study (TCTR20200624007) compared the effects of 6% Pueraria mirifica vaginal gel versus a placebo gel on vaginal blood flow and vaginal maturation index (VMI) in 72 postmenopausal women. After 4 and 12 weeks of treatment, pulsatility index (PI) and resistance index (RI) had significantly decreased in the P. mirifica group compared with the placebo group. Researchers concluded that 6% P. mirifica vaginal gel for 12 weeks in postmenopausal women with genitourinary syndrome of menopause appeared to increase vaginal artery circulation and restore atrophic vaginal tissue.

A 12-week treatment regimen with Pueraria mirifica gel was shown to be efficacious and safe for the treatment of vulvovaginal atrophy; however, conjugated estrogen cream was found to be more effective compared to Pueraria mirifica gel in improving signs of vaginal atrophy and restoring vaginal epithelium at 6 and 12 weeks. This comparison with conventional therapy is important context for understanding relative efficacy.

A broader review of 33 eligible high-quality papers found that various forms of phytoestrogens, including Pueraria mirifica, in oral or vaginal application forms could improve menopausal urogenital symptoms. The recovery rate in vaginal use of these phytoestrogens was greater than with other forms of consumption. After using a variety of phytoestrogens in different forms, indicators of urogenital atrophy and urinary disorders improved and women's sexual function improved after treatment.

Overall evidence strength for vaginal/genitourinary effects: Moderate. Multiple small randomized controlled trials support a beneficial effect, though trials are generally small in size and topical conjugated estrogen remains more effective.

3. Bone Health and Osteoporosis Prevention

Miroestrol (MR) is a highly active phytoestrogen isolated from the tuberous root of Pueraria candollei var. mirifica. Modulatory effects of PM and MR on osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) mRNAs — which are bone-specific genes — were investigated in ovariectomized female ICR mice. Miroestrol (MR) significantly enhanced OPG mRNA expression while suppressing RANKL mRNA in ovariectomized mice. PM extract and MR increased the OPG/RANKL ratio, mitigating osteoporosis progression at the molecular level.

PM crude extract significantly down-regulated the expression of RANKL mRNA with no change in the OPG level, whereas MR elevated the expression of OPG mRNA while lowering the level of RANKL mRNA, resulting in an increased OPG/RANKL ratio, and consequently leading to lower progression of osteoporosis at the molecular level. These findings revealed the potential of PM extract and MR on bone loss prevention via increasing the ratio of OPG to RANKL (osteoformation/osteoresorption) in the liver of ovariectomized mice.

There is also evidence that Pueraria mirifica may support certain aspects of bone health after menopause. Some studies report modest reductions in total and LDL cholesterol and improvements in biochemical markers of bone turnover when women take standardized extracts for several months. These changes hint that the herb may help slow menopause-related shifts in bone metabolism, although actual fracture outcomes have not been tested.

Pueraria mirifica has also been found to decrease serum parathyroid hormone and calcium levels in aged monkeys, suggesting reduced bone loss. Animal studies have shown that Pueraria mirifica can minimize bone loss during menopause.

Overall evidence strength for bone health: Preliminary. Evidence is primarily from animal models (ovariectomized mice and primate studies). Human clinical data on bone mineral density changes or fracture reduction are limited or absent.

4. Cognitive Function

Miroestrol (MR) is a phytoestrogen isolated from Pueraria candollei var. mirifica, a Thai medicinal plant used for rejuvenation. Researchers examined the effects of MR on cognitive function, oxidative brain damage, and the expression of genes encoding brain-derived neurotrophic factor (BDNF) and cyclic AMP-responsive element-binding protein (CREB) — factors implicated in neurogenesis and synaptic plasticity — in ovariectomized (OVX) mice. Ovariectomy also impaired object recognition performance in the novel object recognition test and spatial cognitive performance in the Y-maze test and the water maze test. Daily treatment with MR dose-dependently attenuated OVX-induced cognitive dysfunction.

In a further mouse study, daily treatment with PM and 17β-estradiol (E2) significantly elevated cognitive behavior as evaluated by using the Y maze test, novel object recognition test (NORT), and the Morris water maze test, and attenuated atrophic changes in the uterus. The treatments significantly ameliorated ovariectomy-induced oxidative stress in the hippocampus and serum by a decrease in malondialdehyde (MDA), an enhancement of superoxide dismutase and catalase activity, and significantly down-regulated expression of IL-1β, IL-6 and TNF-α proinflammatory cytokines, while up-regulating expression of PI3K.

Overall evidence strength for cognitive effects: Preliminary. All current evidence is from animal models (ovariectomized rodent models). No human clinical trials have been conducted examining miroestrol specifically for cognitive outcomes.

5. Antioxidant Effects

The crude extract of PM and its active phytoestrogen, miroestrol (MR), were given to OVX mice. The effect on antioxidation enzymes and glutathione (GSH) levels in livers and uteri were examined and compared with the synthetic estradiol hormone. Ovariectomy significantly decreased total GSH content and the ratio of GSH to oxidized glutathione (GSSG) in both the livers and uteri of mice. Moreover, ovariectomy reduced the activities of glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT). These observations support using PM and MR as promising alternative medicine candidates for hormone replacement therapy of estradiol because of their ability to improve GSH levels and the activities of antioxidative enzymes, especially in OVX mice.

Overall evidence strength for antioxidant effects: Preliminary. Evidence is from in vitro and animal studies only. No controlled human trials specifically examining miroestrol's antioxidant effects are reported in the published literature.

6. Cardiovascular and Lipid Metabolism

Flavones from Pueraria roots were found to prevent increases in total cholesterol and triglycerides that typically follow rapid declines in system-wide estrogen levels. This study also showed that Pueraria limits the increase in abdominal fat stores that occur in ovariectomized menopause animal models. Some studies report modest reductions in total and LDL cholesterol and improvements in biochemical markers when women take standardized extracts for several months. These findings are encouraging, but human cardiovascular endpoint studies have not been conducted.

Body Systems and Health Areas Associated with Miroestrol

• Reproductive and Genitourinary System: Pueraria mirifica is used as a health food or in dietary supplements for improving hot flushes and night sweats in perimenopausal/postmenopausal women, and for reducing blood lipids.
• Musculoskeletal System (Bone): There is interest in the plant's role in supporting bone density, especially after menopause when bone loss accelerates due to decreased estrogen. Animal studies have indicated that Pueraria mirifica can help minimize bone loss. The mechanism is thought to involve the phytoestrogens stimulating bone-building cells and inhibiting cells that break down bone tissue, thereby helping to preserve bone mass.
• Nervous System and Cognition: Results from animal studies suggest that PM extract suppresses oxidative brain damage and dysfunctions in the hippocampal antioxidant system, including the neuroinflammatory system in OVX animals, thereby preventing OVX-induced cognitive impairment; PM appears to exert beneficial effects on cognitive deficits for which menopause/ovariectomy have been implicated as risk factors.
• Skin and Connective Tissue: The phytoestrogens in Pueraria mirifica are thought to support collagen production, which can contribute to firmer, more elastic skin and reduce wrinkles. Beyond menopause, there is early-stage research on skin hydration, elasticity, and hair quality, likely linked to estrogen-like effects on collagen and skin structure. Some cosmetic products include Pueraria mirifica in topical formulations, but robust evidence from well-designed trials is limited.
• Cardiovascular System: Evidence from animal and small human studies suggests modest beneficial effects on lipid profiles, though human clinical cardiovascular outcomes data are absent.
• Hepatic and Antioxidant Systems: Standardized crude isoflavonoid extract from P. candollei root cultures and miroestrol have been reported to influence cytochrome P450 activity, lipid peroxidation, and the antioxidation state in the liver and uterus.

Dosage Forms and Reported Dosages

Commercial products are available in topical (creams, gels, and soaps) or oral (capsules or tablets) dosage forms. Some clinical studies used 200 to 400 mg (extracted from the root or tuber) by mouth per day. Commercial manufacturers suggest 250 mg (root or tuber) by mouth every morning and evening.

Continuous administration of PM at 20–100 mg/day for 6 months, or at 100–200 mg/day for 12 months, was found to help women with menopausal symptoms, while no significant changes were detected in hepatic, hematologic, and renal functions.

Based on available studies, a safe dosage of PM as a dietary supplement for humans was suggested at 1–2 mg/kg body weight/day or about 50–100 mg/day. Doses of 20–100 mg/day are commonly used, but in some cases 200–900 mg/day or even higher (up to 3000 mg/day) have been applied.

In one clinical study, patients received oral 50 mg and 100 mg capsules of raw Pueraria mirifica material once daily for six months.

In a randomized, placebo-controlled trial, daily doses of 20–50 mg over 24 weeks improved vaginal dryness, discomfort, and objective measures of vaginal atrophy, with no major short-term safety signals.

For the topical vaginal route, a 6% Pueraria mirifica vaginal gel was studied in a randomized, double-blinded, placebo-controlled trial involving 72 postmenopausal women.

In animal antioxidant studies, female ICR mice were administered daily with estradiol (E2, 0.5 mg/kg/day), or miroestrol (MR, 0.5 or 5 mg/kg/day) for 7 days. These are preclinical doses and cannot be directly extrapolated to humans.

Safety Considerations and Known Interactions

Reproductive and Endocrine Toxicity

Pueraria mirifica's major adverse effect is its reproductive and endocrine toxicity in experimental animals, including monkeys. A human study showed that some subjects developed anaemia and affected liver function.

The safety of using P. mirifica extracts has not been adequately demonstrated, particularly for endocrine and reproductive functions, with adverse effects possibly affecting people with elevated blood lipids, asthma, diabetes mellitus, epilepsy, or systemic lupus erythematosus.

Potential for Carcinogenic Effects at High Doses

Despite the data on the benefits of PM, there are reasons for concern that a herb which exhibits strong estrogen-like properties may stimulate the growth of existing estrogen-sensitive breast or endometrial tumors, raising questions such as: what is a safe dose? Available data call into question the safety of long-term exposure to phytoestrogens with regard to effects on the mammary gland and endometrium.

High doses of Pueraria mirifica may overstimulate estrogen receptors in women at risk of hormone-dependent cancers. Clinical dosage and personal hormone status are critical factors. However, Manonai et al. (2007) found that menopausal women using Pueraria mirifica for six months experienced improvement in hormone-related symptoms without significant changes in mammographic breast density, a marker for breast cancer risk.

High-Dose Adverse Effects

Until now, no serious side effects have been recorded with the prescribed safe dosage, although at high doses PM may cause epilepsy, diabetes, asthma, and migraine.

The use of Pueraria mirifica can be associated with several mild side effects related to its hormonal activity. Some individuals may experience breast tenderness, bloating, or changes in weight. Headaches and irregular menstrual periods have also been reported. More significant safety concerns exist for certain individuals due to the plant's strong estrogen-like properties.

Drug Interactions

No known drug interactions have been formally identified, although research on the effects of phytoestrogens is limited. Given miroestrol's documented influence on cytochrome P450 enzymes, interactions with medications metabolized by those enzymes are plausible but have not been formally characterized in peer-reviewed clinical research.

Populations Requiring Special Caution

If a person has been diagnosed with ER-positive (estrogen receptor-positive) breast cancer, Pueraria mirifica could potentially stimulate cell growth. It is not a "cure" and should never be used as a standalone treatment for cancer.

Pueraria candollei var. mirifica growing in upland Thailand has a long history as a postmenopausal rejuvenating therapy; however, its amelioration of menopause symptoms in clinical trials needs further robust assessment. The overall quality of the available clinical evidence base is limited by small sample sizes, short study durations, and methodological variation across trials.

Regulatory Status

In Thailand, Pueraria mirifica is more commonly available fresh or processed as a dietary supplement than in other countries. In the United States, the Food and Drug Administration had refused an application for use of Pueraria mirifica as a drug, though it circulates widely as a dietary supplement. White Kwao Krua-derived products have been used worldwide as dietary supplements to relieve climacteric symptoms in menopausal women.

Summary of Evidence Strength

• Vaginal/genitourinary atrophy (topical and oral use): Moderate. Multiple small randomized controlled trials support improvement in vaginal atrophy markers and symptoms, though effects are inferior to standard conjugated estrogen.
• Menopausal symptom relief (hot flashes, night sweats): Weak to moderate. The strongest human data are for relief of vaginal atrophy and related symptoms, with secondary signals for lipid and bone markers. Benefits for hot flashes, mood, sleep, and aesthetic effects remain plausible but incompletely documented, and responses vary widely between individuals.
• Bone health: Preliminary. Animal studies show mechanistic plausibility via OPG/RANKL modulation; human fracture or bone density clinical outcome data are absent.
• Cognition: Preliminary/animal only. No human trials for miroestrol-specific cognitive effects.
• Antioxidant and hepatic effects: Preliminary/preclinical. Animal and in vitro data only.

References

• Wikipedia — Miroestrol
• Wikipedia — Pueraria mirifica
• Chansakaow et al. (2000). Identification of Deoxymiroestrol as the Actual Rejuvenating Principle of "Kwao Keur", Pueraria mirifica. Journal of Natural Products.
• Transcriptome analysis of Pueraria candollei var. mirifica for gene discovery in the biosyntheses of isoflavones and miroestrol. BMC Plant Biology / PMC.
• Efficacy and safety of Pueraria candollei var. mirifica for menopausal women: A systematic review of clinical trials. PubMed.
• Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women. PubMed.
• Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause. PubMed.
• Impact of Pueraria candollei var. mirifica and its potent phytoestrogen miroestrol on expression of bone-specific genes in ovariectomized mice. PubMed.
• Effect of miroestrol on ovariectomy-induced cognitive impairment and lipid peroxidation in mouse brain. PubMed.
• Effects of Pueraria mirifica and miroestrol on the antioxidation-related enzymes in ovariectomized mice. PubMed.
• A lateral flow colloidal gold-based immunoassay for rapid detection of miroestrol in samples of White Kwao Krua. PubMed.
• Effects of Pueraria candollei var. mirifica on Ovariectomy-Induced Cognitive Impairment and Oxidative Stress in the Mouse Brain. PMC.
• Pueraria mirifica Exerts Estrogenic Effects in the Mammary Gland and Uterus and Promotes Mammary Carcinogenesis in Donryu Rats. PMC.
• Differential binding with ERα and ERβ of the phytoestrogen-rich plant Pueraria mirifica. SciELO Brazil / Brazilian Journal of Medical and Biological Research.
• Impact of Pueraria candollei var. mirifica and its potent phytoestrogen miroestrol on expression of bone-specific genes in ovariectomized mice. ScienceDirect.
• Improvements of vaginal atrophy without systemic side effects after topical application of Pueraria mirifica in postmenopausal cynomolgus macaques. PubMed.
• Pueraria mirifica for Menopausal Symptom Relief and Tissue Support. Journal of Restorative Medicine.
• Estrogen receptor signaling mechanisms. PMC / NIH.
• Risk in Brief: Thai kudzu (Pueraria mirifica) in "breast boosting" food. Centre for Food Safety, Hong Kong.
• Pueraria Uses, Benefits & Dosage. Drugs.com (medically reviewed).
• Pueraria mirifica: a critical review of the ethnobotany, phytochemistry, pharmacology and challenges in standardization and safety. Frontiers in Pharmacology, 2026.
• A comprehensive review on Pueraria: Insights on its chemistry and medicinal value. ScienceDirect / Biomedicine & Pharmacotherapy.
• Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms. ResearchGate.